Abstract
6073 Background: Oropharyngeal HNSCCa is frequently associated with HPV. We hypothesize that immunotherapy with INO-3112 will generate immune responses in patients (pts) with HPV+ HNSCCa. Methods: This Phase I/IIa trial included pts with p16+ locally advanced HNSCCa, ECOG PS 0-1. INO-3112 was delivered IM along with electroporation with the CELLECTRA device, Q3 weeks x 4 doses. Cohort 1 (C1) pts received INO-3112 pre and post-surgery; Cohort 2 (C2) pts received INO-3112 post cisplatin-based definitive chemoradiation. 1° and 2° endpoints were safety and immune responses. Pre- and post INO-3112 tissue samples (C1) were assessed for tumor infiltrating lymphocytes (TILs). Peripheral immune responses were assessed by ELISA for HPV16/18 specific antibody levels, and by IFNɤ ELISpot for antigen specific response, at each dose visit and q3 months (mos). Results: As of 08/2016, 22 pts were treated, completing accrual. C1: n = 6, C2: n = 16; 20 male, median age 57.5 years (32-76); base of tongue = 10, tonsil = 12; never smoker = 10. All pts are alive, median follow up is 15.9 mos (1-26). INO-3112 was well-tolerated with no related Grade 3-5 AEs. In 5 C1 pts post immunotherapy, increase in CD8+ infiltration into tumor was noted in 2 pts (1.6-3.6 fold) and decrease in FoxP3+ was noted in the other 3 (1.8-2.1 fold). This resulted in positive shift in CD8+/FoxP3+ ratio in neoplastic tissue in 4/5 pts. Peak mean/median antibody responses to HPV16 E7 and HPV18 E7 antigens for 19 evaluable pts were 1:1235/1:150 and 1:2853/1:450, respectively. As compared to baseline, 18 evaluable pts showed elevated HPV16/HPV18 specific T cell activity (by IFNɤ ELISpot), with peak mean/median responses of 179.99/68.33 SFU per 106 PBMC (HPV16) and 107.18/53.3 SFU per 106 PBMC (HPV18). Persistent cellular responses > 100 SFU/106PBMC were noted out to 12 mos. 3 pts have progressed; 1 pt received Nivolumab for progressive disease, and remains in CR. Conclusions: These data show that INO-3112 generates HPV-specific peripheral humoral and cellular immune responses that may persist out to 12 months and influences the composition of CD8+ and FoxP3+ immune infiltration into tumor tissue in HPV+ HNSCCa. Clinical trial information: NCT02163057.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
